The Brazil CMO/CDMO ecosystem is expected to surge at a CAGR of 2.7% in the forecast period 2023 to 2033. Its value is projected to increase from USD 697.93 million in 2023 to USD 907.67 million by 2033. The Brazil CMO/CDMO business was valued at USD 679.10 million at the end of 2022 and is anticipated to exhibit a y-o-y growth of 2.8 % in 2023.
| Attributes | Key Insights |
|---|---|
| Brazil CMO/CDMO Business Size (2022A) | USD 679.10 million |
| Brazil CMO/CDMO Business Estimated Revenue (2023E) | USD 697.93 million |
| Brazil CMO/CDMO Business Projected Revenue (2033F) | USD 907.67 million |
| Value-based CAGR (2023 to 2033) | 2.7% |
Brazil is projected to be one of the most prominent pharmaceutical sectors in Latin America. The surging aging population, rising healthcare costs, and increased public knowledge of healthcare have all contributed to a steady increase in the demand for pharmaceuticals in Brazil.
The government of Brazil has implemented stringent rules to promote regional pharmaceutical production. This includes policies, including tax breaks and privileges for domestically produced goods.
The Brazil CMO/CDMO business has placed a substantial emphasis on the manufacturing of biologics and biosimilars. These sophisticated treatments frequently call for specialist production skills.
For contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) operating in Brazil, compliance with international quality standards, such as Good Manufacturing Practices (GMP), is essential. Both domestic and international sales depend on compliance with regulatory regulations.
Biotech and pharmaceutical companies in Brazil are increasingly using CMOs and CDMOs to handle their manufacturing requirements. The necessity for flexible production capacity, access to specialist knowledge, and cost-effectiveness are a handful of the driving forces behind this outsourcing trend.
CMO/CDMO companies are set to offer manufacturing services to the biotechnology, pharmaceutical, and other industries, as well as help with the production of medical equipment. CMOs are also expected to provide their resources, knowledge, and facilities to make goods for their customers.
The CMO and CDMO sector has seen rapid expansion in recent years. The pharmaceutical and biotechnology industries have seen a rise in the outsourcing of production and development services owing to the advantages of cost savings, flexibility, and access to specialized knowledge.
The Brazil CMO/CDMO business recorded a decent CAGR of 2.0% in the historical period from 2018 to 2022. The value for the CMO/CDMO business in Brazil was around 1.2% of the total USD 56,660.60 million of the global CMO/CDMO business.
The growing pharmaceutical sector is the main factor spurring the Brazil CMO/CDMO business landscape. Increasing approval of manufacturing facilities is set to drive growth.
The total production capacity in Brazil rises as more manufacturing facilities are approved. The increased demand for outsourcing services would enable CMOs and CDMOs to take on additional clients and projects.
The approval of multiple manufacturing facilities, such as those for sterile injectables, biologics, or specialized formulations, can increase the variety of services provided by CMOs and CDMOs. Due to this variety, pharmaceutical companies can select partners who meet their particular requirements.
Manufacturing facilities would become more competitive in the global business landscape as they receive approval. CMOs/CDMOs that can show compliance with international regulatory standards would draw clients from other nations looking for dependable manufacturing partners in addition to Brazil.
The Brazil CMO/CDMO ecosystem has begun to place a lot of emphasis on the manufacturing of biologics and biosimilars. The complexity of these products frequently necessitates specialized production capabilities, and this business category has seen tremendous expansion.
The government of Brazil has also started several programs to encourage expansion in the biotechnology and pharmaceutical sectors. These include tax breaks, research grants, and other forms of assistance to promote industrial investment and innovation.
CMOs and CDMOs in Brazil have started to focus more on research & development services and offering their experience in technological development. They are also aiming to understand analytical testing and process optimization in addition to typical manufacturing services
The table below provides the latest trends observed in the Brazil CMO/CDMO space, growth obstacles, and upcoming opportunities. Business strategies for pushing CMO/CDMO sales in Brazil would enable stakeholders to invest in the right area and gain profit.
| Attributes | Key Factors |
|---|---|
| Latest Trends |
|
| Upcoming Opportunities |
|
| Challenges |
|
The table below shows the share of the top 5 countries for the review period from 2023 to 2033. South and North Brazil are expected to remain dominant by exhibiting CAGRs of 4.5% and 4.9%, respectively. The Central-west and Northeast Brazil are projected to follow with CAGRs of 3.8% and 3.1%, respectively.
Growth Outlook by Key Region
| Regions | Value CAGR |
|---|---|
| Southeast Brazil | 2.3% |
| Northeast Brazil | 3.1% |
| Central-west Brazil | 3.8% |
| South Brazil | 4.5% |
| North Brazil | 4.9% |
Growth in Southeast Brazil’s pharmaceutical sector is expanding steadily. Due to population expansion and improved access to healthcare, there is an increase in local demand for pharmaceuticals and other medical products.
The Southeast area of Brazil is benefiting from initiatives the government has put in place to encourage pharmaceutical business expansion. This includes financial incentives and tax breaks for businesses setting up shop in the region.
Southeast Brazil dominated the CMO/CDMO business and generated a 68.6% share in 2022. It is projected to continue experiencing high growth throughout the forecast period.
The economic center of Brazil is in the southeast, which is home to important cities, such as Sao Paulo and Rio de Janeiro. It is a popular site for CMOs and CDMOs to serve these clients because of its significant industrial base and the large number of pharmaceutical and biotech companies that call it home.
Prestigious universities and research institutions in Southeast Brazil offer a skilled labor pool and chances for collaboration between CMOs/CDMOs and academia on research & development projects. Also, several CMOs/CDMOs based in Southeast Brazil have expanded their operations globally, enabling them to serve clients both domestically and internationally.
A handful of states in Northeast Brazil, such as Pernambuco, have taken special initiatives to draw in investments in the fields of biotechnology and life sciences. This has caused a cluster of biotech businesses to expand, opening doors for CMOs and CDMOs that focus on biologics.
Biotechnology and pharmaceutical research and development have received more attention in the region. This involves the development of formulations, analytical testing, and process optimization, areas in which CMOs and CDMOs can be particularly skilled.
Northeast Brazil dominates the Brazil CMO/CDMO business and held a 19.8% share in 2022. It is projected to continue experiencing high growth throughout the forecast period. Northeast Brazil has special environmental features or natural resources that make biopharmaceutical research and development possible.
Northeast Brazil is also the perfect location for companies focused on biotech and their manufacturing partners backed by these resources. Also, the region is home to eminent research facilities and academic hubs with a focus on biotechnology and pharmaceuticals.
They can promote cooperation between these institutions and CMOs/CDMOs. Such collaborations are frequently necessary to expand research and development initiatives.
Central-west Brazil held about a 5.1% share of the Brazil CMO/CDMO business in 2022. It is projected to increase during the forecast period.
Central-west Brazil's center geographic location offers a logistical advantage, enabling effective pharmaceutical product distribution to multiple regions across Brazil and adjacent nations. For CMOs and CDMOs aiming to serve a large space, this can be a crucial draw.
Investments in infrastructure, including transportation networks and industrial parks, can further enhance the region's attractiveness for pharmaceutical manufacturing and supply chain operations. The government supports domestic medicinal product production.
CMOs and CDMOs in the region would have the chance to serve the home ecosystem and export goods. Several colleges and research facilities in Central-west Brazil offer a pool of qualified workers in fields related to pharmaceutical development and manufacturing. CMOs and CDMOs can benefit from this in terms of hiring new personnel.
The table below signifies leading sub-categories under product, expression, and company size categories in the Brazil CMO/CDMO business. Stand-alone services are expected to dominate the ecosystem for Brazil CMO/CDMO at a CAGR of 3.4% by 2033. Under the company size category, the mid-sized segment is projected to lead the Brazil CMO/CDMO space with a CAGR of 2.3% by 2033.
Growth Outlook by Key Segments
| Segment | Value CAGR |
|---|---|
| Stand-alone Services (Services) | 3.4% |
| API Substrate (Product) | 1.9% |
| Mid-sized (Company Size) | 2.3% |
| Mammalian (Expression System) | 2.7% |
| Commercial (Scale of Operation) | 2.9% |
Stand-alone services under the service category held a share of 42.5% in 2022. It is expected to remain at the forefront over the forecast period.
Stand-alone services focus on specific aspects of drug development and manufacturing, such as formulation development, analytical testing, or sterile manufacturing. This specialization can attract companies seeking expertise in a particular area.
Companies decide to use stand-alone services to cut costs by outsourcing only a portion of the production or development of drugs while maintaining control over the remaining portions. This factor is anticipated to lead the stand-alone service segment in the Brazil CMO/CDMO business.
API substrate under the product category held a considerable share of 41.4% in 2022. The main components of pharmaceutical formulations are APIs.
APIs, often referred to as the dynamic components of medications, underlie their therapeutic effectiveness. The process of crafting APIs holds a pivotal role in the production of pharmaceuticals, marking a critical step in the journey of creating therapeutic solutions.
Pharmaceutical companies find it more affordable to outsource API production. The volume and efficiency of CMOs and CDMOs would allow them to create APIs more cheaply than in-house labs.
For the manufacturing of biologics, such as monoclonal antibodies, recombinant proteins, and vaccines, mammalian expression systems are frequently chosen. Due to their success in treating a wide range of ailments, biologics have grown in terms of popularity in the operating of the pharmaceutical sector.
Mammalian expression systems are set to be necessary for the manufacturing of several advanced and sophisticated medicines, including cell and gene therapies. These treatments are projected to make up a rapidly expanding area for pharmaceuticals. This factor is expected to stimulate the mammalian segment over the forecast timeline.
Geographic expansions are a priority for leading CMO/CDMO companies in Brazil as they work to create new product lines and expand their global consumer base. Expansion and acquisition among key companies or brands is the leading strategy of manufacturers such as Catalent and Fragon.
They aim to enhance their presence in the business landscape and compete with other players during the forecast period. Following are a handful of recent developments:
For instance,
| Attribute | Details |
|---|---|
| Brazil CMO-CDMO Revenue (2022) | USD 679.10 million |
| Projected Brazil CMO-CDMO Revenue (2033) | USD 907.67 million |
| Value-based CAGR (2023 to 2033) | 2.7% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Business Analysis | Value (USD million) |
| Key Regions Covered | North Brazil; Northeast Brazil; Central-west Brazil; Southeast Brazil; and South Brazil |
| Key Segments Covered | Services, Product, Expression System, Company Size, Scale of Operation, Region |
|
Key Companies Profiled |
Lonza AG; Unither Pharmaceuticals; Catalent Inc.; Fagron; Eurofarma; Pfizer CentreOne; Patheon N.V. (Thermo Fisher Scientific, Inc.); NUVISAN; Societal CDMO; Bio-Manguinhos; Biotimize; Pierre Fabre group; Ajinomoto Co., Inc. |
Table 01: Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 02: Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 03: Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 04: Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 05: Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 06: Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
Table 07: Business, Cross Sectional Analysis of Product Vs Services, 2018 to 2033
Table 08: Business, Cross Sectional Analysis of Product Vs Services, 2018 to 2033
Table 09: Business, Cross Sectional Analysis of Product Vs Services, 2018 to 2033
Table 10: North Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 11: North Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 12: North Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 13: North Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 14: North Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 15: Northeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 16: Northeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 17: Northeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 18: Northeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 19: Northeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 20: Central-West Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 21: Central-West Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 22: Central-West Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 23: Central-West Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 24: Central-West Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 25: Southeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 26: Southeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 27: Southeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 28: Southeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 29: Southeast Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Table 30: South Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services
Table 31: South Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
Table 32: South Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Expression System
Table 33: South Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Company Size
Table 34: South Size (USD million) Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale of Operation
Figure 01: Split By Region, 2023 (E)
Figure 02: Split By Services, 2023 (E)
Figure 03: Split By Product, 2023 (E)
Figure 04: Split By Expression System, 2023 (E)
Figure 05: Split By Company Size, 2023 (E)
Figure 06: Split By Scale of Operation, 2023 (E)
Figure 07: Historical Value (USD million) Analysis, 2018 to 2022
Figure 08: Value (USD million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 09: Absolute USD Opportunity, 2023 to 2033
Figure 10: Share Analysis (%) By Services, 2023 to 2033
Figure 11: Y-o-Y Growth (%) By Services, 2023 to 2033
Figure 12: Attractiveness Analysis, By Services
Figure 13: Share Analysis (%) By Product, 2023 to 2033
Figure 14: Y-o-Y Growth (%) By Product, 2023 to 2033
Figure 15: Attractiveness Analysis, By Product
Figure 16: Share Analysis (%) By Expression System, 2023 to 2033
Figure 17: Y-o-Y Growth (%) By Expression System, 2023 to 2033
Figure 18: Attractiveness Analysis, By Expression System
Figure 19: Share Analysis (%) By Company Size, 2023 to 2033
Figure 20: Y-o-Y Growth (%) By Company Size 2023 to 2033
Figure 21: Attractiveness Analysis, By Company Size
Figure 22: Share Analysis (%) By Scale of Operation, 2023 to 2033
Figure 23: Y-o-Y Growth (%) By Scale of Operation, 2023 to 2033
Figure 24: Attractiveness Analysis, By Scale of Operation
Figure 25: Share Analysis (%) By Region, 2023 to 2033
Figure 26: Y-o-Y Growth (%) By Region, 2023 to 2033
Figure 27: Attractiveness Analysis, By Region
Figure 28: North Split By Services, 2023 (E)
Figure 29: North Split By Product, 2023 (E)
Figure 30: North Split By Expression System, 2023 (E)
Figure 31: North Split By Company Size, 2023 (E)
Figure 32: North Split By Scale of Operation, 2023 (E)
Figure 33: North Historical Value (USD million) Analysis, 2018 to 2022
Figure 34: North Value (USD million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 35: North Attractiveness Analysis, By Services
Figure 36: North Attractiveness Analysis, By Product
Figure 37: North Attractiveness Analysis, By Expression System
Figure 38: North Attractiveness Analysis, By Company Size
Figure 39: North Attractiveness Analysis, By Scale of Operation
Figure 40: Northeast Split By Services, 2023 (E)
Figure 41: Northeast Split By Product, 2023 (E)
Figure 42: Northeast Split By Expression System, 2023 (E)
Figure 43: Northeast Split By Company Size, 2023 (E)
Figure 44: Northeast Split By Scale of Operation, 2023 (E)
Figure 45: Northeast Historical Value (USD million) Analysis, 2018 to 2022
Figure 46: Northeast Value (USD million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 47: Northeast Attractiveness Analysis, By Services
Figure 48: Northeast Attractiveness Analysis, By Product
Figure 49: Northeast Attractiveness Analysis, By Expression System
Figure 50: Northeast Attractiveness Analysis, By Company Size
Figure 51: Northeast Attractiveness Analysis, By Scale of Operation
Figure 52: Central-West Split By Services, 2023 (E)
Figure 53: Central-West Split By Product, 2023 (E)
Figure 54: Central-West Split By Expression System, 2023 (E)
Figure 55: Central-West Split By Company Size, 2023 (E)
Figure 56: Central-West Split By Scale of Operation, 2023 (E)
Figure 57: Central-West Historical Value (USD million) Analysis, 2018 to 2022
Figure 58: Central-West Value (USD million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 59: Central-West Attractiveness Analysis, By Services
Figure 60: Central-West Attractiveness Analysis, By Product
Figure 61: Central-West Attractiveness Analysis, By Expression System
Figure 62: Central-West Attractiveness Analysis, By Company Size
Figure 63: Central-West Attractiveness Analysis, By Scale of Operation
Figure 64: Southeast Split By Services, 2023 (E)
Figure 65: Southeast Split By Product, 2023 (E)
Figure 66: Southeast Split By Expression System, 2023 (E)
Figure 67: Southeast Split By Company Size, 2023 (E)
Figure 68: Southeast Split By Scale of Operation, 2023 (E)
Figure 69: Southeast Historical Value (USD million) Analysis, 2018 to 2022
Figure 70: Southeast Value (USD million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 71: Southeast Attractiveness Analysis, By Services
Figure 72: Southeast Attractiveness Analysis, By Product
Figure 73: Southeast Attractiveness Analysis, By Expression System
Figure 74: Southeast Attractiveness Analysis, By Company Size
Figure 75: Southeast Attractiveness Analysis, By Scale of Operation
Figure 76: South Split By Services, 2023 (E)
Figure 77: South Split By Product, 2023 (E)
Figure 78: South Split By Expression System, 2023 (E)
Figure 79: South Split By Company Size, 2023 (E)
Figure 80: South Split By Scale of Operation, 2023 (E)
Figure 81: South Historical Value (USD million) Analysis, 2018 to 2022
Figure 82: South Value (USD million), 2023 to 2033 & Y-o-Y Growth Trend Analysis
Figure 83: South Attractiveness Analysis, By Services
Figure 84: South Attractiveness Analysis, By Product
Figure 85: South Attractiveness Analysis, By Expression System
Figure 86: South Attractiveness Analysis, By Company Size
Figure 87: South Attractiveness Analysis, By Scale of Operation
Brazil was valued at around USD 679.10 million in 2022.
Brazil is set to reach a valuation of around USD 907.67 million by 2033.
The API substrate segment held around 41.4% share in 2022.
Brazil's CMO/CDMO space increased at a 2.0% CAGR from 2018 to 2022.
The Brazil CMO/CDMO business is set to reach USD 697.93 million by 2023.
Southeast Brazil CMO/CDMO business held a 68.6% share in 2022.
Lonza AG and Unither Pharmaceuticals are the key exporters of CMO/CDMO in Brazil.
Explore Similar Insights
CMO/CDMO Industry Analysis in Brazil
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
